List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9464736/publications.pdf Version: 2024-02-01



CEN SOBLE

#	Article	IF	CITATIONS
1	Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy. Neuron, 2002, 35, 843-854.	8.1	452
2	X-LINKED RECESSIVE BULBOSPINAL NEURONOPATHY. Brain, 1989, 112, 209-232.	7.6	396
3	17-AAC, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Medicine, 2005, 11, 1088-1095.	30.7	363
4	Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nature Genetics, 2019, 51, 1215-1221.	21.4	328
5	Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Medicine, 2003, 9, 768-773.	30.7	286
6	Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of nonâ€systemic vasculitic neuropathy: executive summary. Journal of the Peripheral Nervous System, 2010, 15, 176-184.	3.1	276
7	Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain, 2016, 139, 3170-3186.	7.6	268
8	Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain, 2006, 129, 1446-1455.	7.6	245
9	Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics, 2004, 13, 1183-1192.	2.9	234
10	Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Annals of Neurology, 2005, 57, 236-251.	5.3	231
11	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	10.2	193
12	Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain, 2005, 128, 659-670.	7.6	182
13	Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 875-884.	10.2	170
14	Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain, 2013, 136, 1371-1382.	7.6	168
15	Spatiotemporal Recapitulation of Central Nervous System Development by Murine Embryonic Stem Cell-Derived Neural Stem/Progenitor Cells. Stem Cells, 2008, 26, 3086-3098.	3.2	162
16	Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology, 2011, 76, 1372-1376.	1.1	162
17	Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 465-473.	1.9	151
18	Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology, 2009, 65, 140-150.	5.3	147

#	Article	IF	CITATIONS
19	Clinicopathological features of neuropathy associated with lymphoma. Brain, 2013, 136, 2563-2578.	7.6	146
20	Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nature Medicine, 2012, 18, 1136-1141.	30.7	139
21	Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology, 2001, 56, 1727-1732.	1.1	136
22	CHIP Overexpression Reduces Mutant Androgen Receptor Protein and Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model. Journal of Neuroscience, 2007, 27, 5115-5126.	3.6	136
23	FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization. Nature Communications, 2015, 6, 7098.	12.8	129
24	Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. Acta Neuropathologica, 1990, 79, 402-408.	7.7	116
25	HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease. Scientific Reports, 2016, 6, 31895.	3.3	111
26	Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurology, The, 2018, 17, 519-529.	10.2	111
27	Neuronal intranuclear inclusion disease cases with leukoencephalopathy diagnosed via skin biopsy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 354-356.	1.9	106
28	Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Progress in Neurobiology, 2012, 99, 246-256.	5.7	99
29	Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2009, 276, 163-169.	0.6	98
30	Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 53-62.	3.0	98
31	Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2527.e11-2527.e16.	3.1	98
32	GGC Repeat Expansion of <i>NOTCH2NLC</i> in Adult Patients with Leukoencephalopathy. Annals of Neurology, 2019, 86, 962-968.	5.3	98
33	dnc-1/dynactin 1 Knockdown Disrupts Transport of Autophagosomes and Induces Motor Neuron Degeneration. PLoS ONE, 2013, 8, e54511.	2.5	85
34	Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology, 2016, 87, 2220-2229.	1.1	85
35	TDP-43 Depletion Induces Neuronal Cell Damage through Dysregulation of Rho Family GTPases. Journal of Biological Chemistry, 2009, 284, 22059-22066.	3.4	84
36	Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology, 2005, 64, 1471-1475.	1.1	76

#	Article	IF	CITATIONS
37	Disrupted Transforming Growth Factor-β Signaling in Spinal and Bulbar Muscular Atrophy. Journal of Neuroscience, 2010, 30, 5702-5712.	3.6	76
38	Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 230-236.	1.7	76
39	Reorganization of brain networks and its association with general cognitive performance over the adult lifespan. Scientific Reports, 2019, 9, 11352.	3.3	66
40	3′UTR Length-Dependent Control of SynGAP Isoform α2 mRNA by FUS and ELAV-like Proteins Promotes Dendritic Spine Maturation and Cognitive Function. Cell Reports, 2017, 20, 3071-3084.	6.4	64
41	Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology, 2018, 91, 1051-1060.	1.1	64
42	Age associated axonal features in HNPP with 17p11.2 deletion in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1109-1114.	1.9	62
43	YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology. Nature Communications, 2020, 11, 507.	12.8	62
44	Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology, 2002, 58, 979-982.	1.1	61
45	Neuronal intranuclear hyaline inclusion disease showing motor-sensory and autonomic neuropathy. Neurology, 2005, 65, 1538-1543.	1.1	60
46	Clinicopathologic features of folate-deficiency neuropathy. Neurology, 2015, 84, 1026-1033.	1.1	60
47	Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology, 2020, 94, e1726-e1737.	1.1	58
48	Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain, 2012, 135, 2838-2848.	7.6	57
49	Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology, 2014, 82, 255-262.	1.1	57
50	Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Molecular Medicine, 2012, 18, 1261-1268.	4.4	56
51	Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 988-996.	1.9	56
52	A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study. Neuromuscular Disorders, 2015, 25, 554-562.	0.6	50
53	Microarray Analysis of Gene Expression by Skeletal Muscle of Three Mouse Models of Kennedy Disease/Spinal Bulbar Muscular Atrophy. PLoS ONE, 2010, 5, e12922.	2.5	49
54	Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiology of Aging, 2016, 39, 219.e1-219.e8.	3.1	49

#	Article	IF	CITATIONS
55	A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Communications Biology, 2020, 3, 526.	4.4	49
56	Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance Anti-Myelin-Associated Glycoprotein Neuropathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1143-1157.	1.7	48
57	Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics, 2015, 24, 5985-5994.	2.9	48
58	Markers for Guillainâ€Barré syndrome with poor prognosis: a multiâ€center study. Journal of the Peripheral Nervous System, 2017, 22, 433-439.	3.1	46
59	Axonal pathology in Japanese Guillainâ€Bard syndrome. Neurology, 1997, 48, 1694-1700.	1.1	45
60	Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nature Communications, 2013, 4, 1405.	12.8	45
61	An unbiased data-driven age-related structural brain parcellation for the identification of intrinsic brain volume changes over the adult lifespan. NeuroImage, 2018, 169, 134-144.	4.2	44
62	Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1026-1032.	1.9	40
63	Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nature Medicine, 2012, 18, 1531-1538.	30.7	39
64	Severe hyposmia and aberrant functional connectivity in cognitively normal Parkinson's disease. PLoS ONE, 2018, 13, e0190072.	2.5	39
65	Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Annals of Clinical and Translational Neurology, 2016, 3, 537-546.	3.7	38
66	Gene Expressions Specifically Detected in Motor Neurons (Dynactin 1, Early Growth Response 3,) Tj ETQq0 0 0 Markers in Sporadic Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2007, 66, 617-627	rgBT /Over 1.7	lock 10 Tf 50 36
67	Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case. Acta Neuropathologica, 1992, 84, 171-177.	7.7	35
68	Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson's disease. Journal of Neurology, 2018, 265, 688-700.	3.6	34
69	Changes in white matter fiber density and morphology across the adult lifespan: A crossâ€sectional fixelâ€based analysis. Human Brain Mapping, 2020, 41, 3198-3211.	3.6	34
70	Lower Motor Neuron Involvement in TAR DNA-Binding Protein of 43 kDa–Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 172.	9.0	33
71	A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of <i>TTN</i> . Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 851-858.	1.9	33
72	Structural MRI correlates of amyotrophic lateral sclerosis progression. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 901-907.	1.9	33

#	Article	IF	CITATIONS
73	MRI Demonstrates Dorsal Column Involvement of the Spinal Cord in Sjogren's syndrome-associated Neuropathy. Neurology, 1995, 45, 592-593.	1.1	32
74	Nonmyelinating Schwann Cell Involvement With Well-Preserved Unmyelinated Axons in Charcot-Marie-Tooth Disease Type 1A. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1027-1036.	1.7	32
75	Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded and rogen receptors. Human Molecular Genetics, 2015, 24, 314-329.	2.9	32
76	TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. Journal of Clinical Investigation, 2019, 129, 3578-3593.	8.2	32
77	Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 650-659.	1.9	31
78	Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology, 2018, 90, e1501-e1509.	1.1	30
79	Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 285-290.	1.9	30
80	Memory Loss and Frontal Cognitive Dysfunction in a Patient with Adult-onset Neuronal Intranuclear Inclusion Disease. Internal Medicine, 2016, 55, 2281-2284.	0.7	28
81	Chronic progressive sensory ataxic neuropathy with polyclonal gammopathy and disseminated focal perivascular cellular infiltrations. Neurology, 1988, 38, 463-463.	1.1	26
82	Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2016, 263, 1129-1136.	3.6	25
83	A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease. Scientific Reports, 2019, 9, 10104.	3.3	25
84	Nerve growth factor receptor immunoreactivity in the neuronal perikarya of human sensory and sympathetic nerve ganglia. Neurology, 1989, 39, 937-937.	1.1	24
85	Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 571-579.	1.7	23
86	Molecular Pathophysiology and Disease-Modifying Therapies for Spinal and Bulbar Muscular Atrophy. Archives of Neurology, 2012, 69, 436.	4.5	22
87	Semantic deficits in ALS related to right lingual/fusiform gyrus network involvement. EBioMedicine, 2019, 47, 506-517.	6.1	22
88	Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy. PLoS ONE, 2016, 11, e0168846.	2.5	22
89	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials, 2016, 17, 345.	1.6	21
90	FXTAS is difficult to differentiate from neuronal intranuclear inclusion disease through skin biopsy: a case report. BMC Neurology, 2021, 21, 396.	1.8	21

#	Article	IF	CITATIONS
91	Characteristics of Neural Network Changes in Normal Aging and Early Dementia. Frontiers in Aging Neuroscience, 2021, 13, 747359.	3.4	20
92	Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. Journal of Neurology, 2012, 259, 712-719.	3.6	19
93	Neuronal Intranuclear Inclusion Disease Presenting with Resting Tremor. Case Reports in Neurology, 2014, 6, 176-180.	0.7	19
94	Identifying the brain's connector hubs at the voxel level using functional connectivity overlap ratio. NeuroImage, 2020, 222, 117241.	4.2	19
95	Unveiling synapse pathology in spinal bulbar muscular atrophy by genome-wide transcriptome analysis of purified motor neurons derived from disease specific iPSCs. Molecular Brain, 2020, 13, 18.	2.6	19
96	Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e407.	6.0	18
97	Marked Involvement of the Striatal Efferent System in TAR DNA-Binding Protein 43 kDa-Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2016, 75, 801-811.	1.7	17
98	Case of adult-onset neuronal intranuclear hyaline inclusion disease with negative electroretinogram. Documenta Ophthalmologica, 2017, 134, 221-226.	2.2	17
99	Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology, 2019, 92, e1868-e1877.	1.1	17
100	ANCA-Associated Vasculitic Neuropathies: A Review. Neurology and Therapy, 2022, 11, 21-38.	3.2	17
101	DNA methylation inhibitor attenuates polyglutamineâ€induced neurodegeneration by regulating Hes5. EMBO Molecular Medicine, 2019, 11, .	6.9	16
102	Aging Impacts the Overall Connectivity Strength of Regions Critical for Information Transfer Among Brain Networks. Frontiers in Aging Neuroscience, 2020, 12, 592469.	3.4	16
103	Cerebello-basal ganglia connectivity fingerprints related to motor/cognitive performance in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 80, 21-27.	2.2	15
104	Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2022, 269, 885-896.	3.6	15
105	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain, 2022, 145, 2769-2784.	7.6	15
106	Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Science Advances, 2022, 8, .	10.3	15
107	Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nature Communications, 2019, 10, 4262.	12.8	13
108	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13

#	Article	IF	CITATIONS
109	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1339-1342.	1.9	13
110	Bridging large-scale cortical networks: Integrative and function-specific hubs in the thalamus. IScience, 2021, 24, 103106.	4.1	13
111	Uncompacted Myelin Lamellae and Nodal Ion Channel Disruption in POEMS Syndrome. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1127-1136.	1.7	12
112	Pathologic Involvement of Glutamatergic Striatal Inputs From the Cortices in TAR DNA-Binding Protein 43 kDa-Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 759-768.	1.7	12
113	Reply: Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. Brain, 2017, 140, e52-e52.	7.6	12
114	Crossâ€sectional and longitudinal analysis of an oxidative stress biomarker for spinal and bulbar muscular atrophy. Muscle and Nerve, 2012, 46, 692-697.	2.2	11
115	Restoration of a Conduction Block after the Long-term Treatment of CIDP with Anti-neurofascin 155 Antibodies: Follow-up of a Case over 23 Years. Internal Medicine, 2018, 57, 2061-2066.	0.7	11
116	Patientâ€reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. European Journal of Neurology, 2020, 27, 196-203.	3.3	11
117	Genetic and functional analysis of KIF5A variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 97, 147.e11-147.e17.	3.1	11
118	The neural network basis of altered decisionâ€making in patients with amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 2115-2126.	3.7	10
119	Case of Neuronal Intranuclear Inclusion Disease With Dynamic Perfusion Changes Lacking Typical Signs on Diffusion-Weighted Imaging. Neurology: Genetics, 2021, 7, e601.	1.9	9
120	Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Research Protocols, 2018, 7, e69.	1.0	9
121	Functional evaluation of PDGFB-variants in idiopathic basal ganglia calcification, using patient-derived iPS cells. Scientific Reports, 2019, 9, 5698.	3.3	8
122	Functional connector hubs in the cerebellum. NeuroImage, 2022, 257, 119263.	4.2	8
123	Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. Journal of the Neurological Sciences, 2021, 421, 117305.	0.6	6
124	Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2022, 113, 131-136.	3.1	6
125	DNA damage in embryonic neural stem cell determines FTLDs' fate via early-stage neuronal necrosis. Life Science Alliance, 2021, 4, e202101022.	2.8	5
126	Fiberâ€specific white matter analysis reflects upper motor neuron impairment in amyotrophic lateral sclerosis. European Journal of Neurology, 2022, 29, 432-440.	3.3	5

#	Article	IF	CITATIONS
127	Effects of Head Motion on the Evaluation of Age-related Brain Network Changes Using Resting State Functional MRI. Magnetic Resonance in Medical Sciences, 2021, 20, 338-346.	2.0	5
128	Association Between IL-5 Levels and the Clinicopathologic Features of Eosinophilic Granulomatosis With Polyangiitis. Neurology, 2021, 96, 226-229.	1.1	5
129	Clinicoradiological features in amyotrophic lateral sclerosis patients with olfactory dysfunction. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 260-266.	1.7	4
130	Safety and Clinical Benefits of Laryngeal Closure in Patients with Amyotrophic Lateral Sclerosis. Dysphagia, 2023, 38, 211-219.	1.8	4
131	Age-related impairment in Addenbrooke's cognitive examination revised scores in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 578-584.	1.7	3
132	Individual changes in visual performance in non-demented Parkinson's disease patients: a 1-year follow-up study. Journal of Neural Transmission, 2020, 127, 1387-1397.	2.8	3
133	Instability of speech in Parkinson disease patients with subthalamic nucleus deep brain stimulation. Parkinsonism and Related Disorders, 2021, 93, 8-11.	2.2	3
134	Analysis of relapse by inflammatory Raschâ€built overall disability scale status in the <scp>PATH</scp> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2022, 27, 159-165.	3.1	3
135	Reply to " <scp>GGC</scp> Repeat Expansion of <scp><i>NOTCH2NLC</i></scp> is Rare in European Leukoencephalopathy― Annals of Neurology, 2020, 88, 642-643.	5.3	2
136	Nerve biopsy in acquired neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S21-S41.	3.1	2
137	Resting State Networks Related to the Maintenance of Good Cognitive Performance During Healthy Aging. Frontiers in Human Neuroscience, 2021, 15, 753836.	2.0	1
138	Serial MRI of olivary hypertrophy: long-term follow-up of a patient with the ?top of the basilar? syndrome. Neuroradiology, 1995, 37, 427-428.	2.2	1
139	4. Pathogenesis and Treatment of Dementia. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1804-1809.	0.0	0